Skip to main content

Year: 2023

Yara invests in CCS in Sluiskil and signs binding CO2 transport and storage agreement with Northern Lights – the world’s first cross-border CCS-agreement in operation

Oslo, 20 November 2023: Yara International, a leading global ammonia player, and Northern Lights, a CO2 transport and storage supplier, sign a binding commercial agreement, enabling the first cross-border transportation and storage of CO2. Yara aims to reduce its annual CO2-emissions by 800,000 tons from the ammonia production at Yara Sluiskil. The CO2 will be liquefied and shipped by Northern Lights from the Netherlands to permanent storage on the Norwegian continental shelf, 2.6 kilometres under the seabed. – This is a milestone for decarbonizing hard-to-abate industry in Europe and for Yara it’s an important step towards decarbonizing our ammonia production, product lines and the food value chain at large, says Svein Tore Holsether, CEO of Yara International. – We are very pleased that Yara has selected Northern Lights as...

Continue reading

Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema

  Regulated information – Inside information Despite Prior Positive Data, THR-149 Did Not Demonstrate Improvement in Vision Oxurion’s Board has Decided to Take Necessary Steps to File for Bankruptcy Leuven, BELGIUM, Boston, MA, US – November 20, 2023 – 7:00 am CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company announced today that topline data in its KALAHARI Phase 2, Part B clinical trial for diabetic macular edema (DME) (KALAHARI trial) did not demonstrate that its novel PKal Inhibitor, THR-149, improved vision as much as the comparator, the anti-VEGF therapy aflibercept, at Month 3 (the primary endpoint). The mean change in best corrected visual acuity (BCVA) from baseline at Month 3 was -0.2 letters for the THR-149 arm and +3.5 letters for the aflibercept arm. The results confirmed that THR-149 was safe and well...

Continue reading

Yara invests in CCS in Sluiskil and signs binding CO2 transport and storage agreement with Northern Lights – the world’s first cross-border CCS-agreement in operation

Northern Lights storage tanksNorthern Lights storage tanks. Photo: Northern lights and Svein Ove Søreide.Northern Lights jettyNorthern Lights jetty. Photo: Northern lights and Svein Ove Søreide.Northern Lights onshore pipelineNorthern Lights onshore pipeline. Photo: Northern Lights and Svein Ove Søreide.Northern Lights storage tanksNorthern Lights storage tanks. Photo: Northern Lights and Svein Ove Søreide.Oslo, 20 November 2023: Yara International, a leading global ammonia player, and Northern Lights, a CO2 transport and storage supplier, sign a binding commercial agreement, enabling the first cross-border transportation and storage of CO2. Yara aims to reduce its annual CO2-emissions by 800,000 tons from the ammonia production at Yara Sluiskil. The CO2 will be liquefied and shipped by Northern Lights...

Continue reading

Biodegradable Cutlery Market to Hit USD 61.6 Million by 2030 | Driven by a Strong 7.2% CAGR

Companies leading the Biodegradable Cutlery Market are Huhtamäki Oyj (Finland), Pactiv Evergeen Inc. (U.S.), Vegware Ltd. (U.K.), Biotrem (Poland), BioPak (Australia), Genpak, LLC (U.S.), TIPA Ltd. (Israel), Ecoware (India), Better Earth LLC (U.S.), BeGreen Packaging (U.S.), and more.Biodegradable Cutlery MarketBiodegradable Cutlery MarketPune, India, Nov. 20, 2023 (GLOBE NEWSWIRE) — The global biodegradable cutlery market size stood at USD 35.85 million in 2022 and is predicted to rise from USD 37.73 million in 2023 to USD 61.6 million by 2030, registering a CAGR of 7.2% from 2023 to 2030. Increasing preference for biodegradable cutlery over plastic tableware due to its sustainability and eco-friendly nature is driving market growth. Degradability, biocompatibility, and biological safety are the significant benefits...

Continue reading

Hair Dryer Market Size to Hit USD 13.42 Billion by 2030 | With a 5.87% CAGR

Key companies covered in hair dryer market are Conair LLC (U.S.), Panasonic Holdings Corporation (Japan), Koninklijke Philips N.V (Netherlands), Dyson Limited (Singapore), Tescom Co., Ltd. (Japan), Spectrum Brands, Inc. (U.S.), Revlon Inc. (U.S.), Ghd Hair (U.K.), Harry Josh Pro Tools (U.S.), Havells (India), and more players profiled.Hair Dryer MarketHair Dryer MarketPune, India, Nov. 20, 2023 (GLOBE NEWSWIRE) — The global hair dryer market size was valued at USD 8.54 billion in 2022 and is expected to be worth USD 9.01 billion in 2023. The market is projected to reach USD 13.42 billion by 2030, recording a CAGR of 5.87% during the forecast period. Hair dryers are a hair styling equipment widely used by hair stylists across the world to dry wet hair and create several unique and elegant hairstyles. They are considered...

Continue reading

Digital Pathology Market Size to Surpass USD 2,694.6 Million by 2030, at a CAGR of 14.9%

As per the report by Fortune Business Insights, The global digital pathology market size was valued at USD 908.9 million in 2022 and is expected to be worth USD 1,019.4 million in 2023. The market is projected to reach USD 2,694.6 million by 2030, recording a CAGR of 14.9% during the forecast period.Digital Pathology MarketForecast 2023-2030Pune, India, Nov. 20, 2023 (GLOBE NEWSWIRE) — The global digital pathology market size was valued at USD 908.9 million in 2022 The market is projected to reach USD 2,694.6 million by 2030 recording a CAGR of 14.9% during forecast period. Digital pathology uses various advanced tools to gather, interpret, analyze, and share critical medical information. Digital slides are created either with a digital microscope or by using whole slide scanning devices from previously prepared devices....

Continue reading

Cardiac Troponin Market Size to Surpass USD 5.17 Billion by 2030, exhibiting a CAGR of 8.1%

According to the report by Fortune Business Insights, the global cardiac troponin market size is projected to reach USD 5.17 billion by 2030, at a CAGR of 8.1% during the forecast period, 2023-2030Cardiac Troponin MarketCardiac Troponin Market Forecast, 2023-2030Pune, India, Nov. 20, 2023 (GLOBE NEWSWIRE) — The global cardiac troponin market is projected to grow from USD 3.01 billion in 2023 to USD 5.17 billion by 2030, exhibiting a CAGR of 8.1% during the forecast period. The growing point-of-care test adoption in hospital emergency departments is expected to drive the cardiac troponin market growth during the projected period. Fortune Business Insights™ mentioned this in a report titled, “Cardiac Troponin Market, 2023-2030.”Request a Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/cardiac-troponin-market-101234Key...

Continue reading

Smart Insulin Pens Market Size to Surpass USD 1,514.6 Million by 2030, exhibiting a CAGR of 10.4%

According to the report by Fortune Business Insights, the global Smart Insulin Pens Market size is projected to reach USD 1,514.6 Million by 2030, at a CAGR of 10.4% during the forecast period, 2023-2030Smart Insulin Pens MarketSmart Insulin Pens Market Forecast 2023-2030Pune, India, Nov. 20, 2023 (GLOBE NEWSWIRE) — The smart insulin pens market is expected to expand from USD 755.4 million in 2023 to USD 1,514.6 million by 2030, exhibiting a CAGR of 10.4% over the study period. Smart insulin pens help track the amount of insulin injected and time, enabling users to input carbohydrate intake, glucose levels, and exercise regimens. Fortune Business Insights™ provides this information in its research report, titled “Smart Insulin Pens Market, 2023-2030”.   Request a Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/smart-insulin-pens-market-108566Key...

Continue reading

Dialysis Market Size to Surpass USD 150.84 Billion by 2030, at a CAGR of 6.8%

As per the report by Fortune Business Insights, The Dialysis Market size is projected to reach USD 150.84 Billion by 2030, at a CAGR of 6.8% during the forecast period.Dialysis MarketDialysis Market (2023-2030)Pune, India, Nov. 20, 2023 (GLOBE NEWSWIRE) — The global dialysis market size was valued at USD 94.43 billion in 2022 and is expected to be worth USD 95.22 billion in 2023 and it is projected to reach USD 150.84 billion by 2030, recording a CAGR of 6.8% during the forecast period. Dialysis products and services have gained major traction in recent years due to the growing prevalence of Chronic Kidney Diseases (CKD). The number of patients visiting renal care clinics is increasing every year, and many of them are opting for this treatment, which has boosted the demand for products, such as hemodialysis machines....

Continue reading

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

LA JOLLA, Calif., Nov. 19, 2023 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s collaborator, Justin Lathia PhD, Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at Cleveland Clinic Lerner Research Institute, and Professor, Department of Molecular Medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and Patrick Wen, Director at the Center for Neuro-Oncology at Dana-Farber Cancer Institute, Professor of Neurology, Harvard Medical School, presented new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) patients at the 28th Annual Meeting of the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.